lopinavir has been researched along with Torsade de Pointes in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (60.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ackerman, MJ; Friedman, PA; Giudicessi, JR; Noseworthy, PA | 1 |
| Andini, R; Bertolino, L; Corcione, A; Durante-Mangoni, E; Florio, LL; Mele, F; Murino, P; Zampino, R | 1 |
| Carron, J; Hussein, H; Kennedy, M; McAdam, B; Sharif, Z; Sheahan, R | 1 |
| Huttner, A; Lüthi, B; Mueller, NJ; Speck, RF | 1 |
1 review(s) available for lopinavir and Torsade de Pointes
| Article | Year |
|---|---|
Clinical guidance for navigating the QTc-prolonging and arrhythmogenic potential of pharmacotherapy during the COVID-19 pandemic.
Topics: Anti-Bacterial Agents; Antiviral Agents; Azithromycin; COVID-19 Drug Treatment; Drug Combinations; Electrocardiography; Enzyme Inhibitors; Humans; Hydroxychloroquine; Long QT Syndrome; Lopinavir; Magnesium; Pandemics; Potassium; Practice Guidelines as Topic; Risk Assessment; Risk Factors; Ritonavir; SARS-CoV-2; Torsades de Pointes | 2021 |
4 other study(ies) available for lopinavir and Torsade de Pointes
| Article | Year |
|---|---|
Urgent Guidance for Navigating and Circumventing the QTc-Prolonging and Torsadogenic Potential of Possible Pharmacotherapies for Coronavirus Disease 19 (COVID-19).
Topics: Anti-Infective Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Death, Sudden, Cardiac; Drug Combinations; Drug Monitoring; Drug Repositioning; Electrocardiography; Humans; Hydroxychloroquine; Long QT Syndrome; Lopinavir; Pandemics; Pneumonia, Viral; Risk Adjustment; Ritonavir; SARS-CoV-2; Torsades de Pointes | 2020 |
Early experience with remdesivir in SARS-CoV-2 pneumonia.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Chemical and Drug Induced Liver Injury; Convalescence; Coronavirus Infections; COVID-19; Critical Illness; Darunavir; Drug Administration Schedule; Drug Combinations; Fatal Outcome; Humans; Hydroxychloroquine; Lopinavir; Multiple Organ Failure; Pandemics; Pneumonia, Viral; Ritonavir; RNA, Viral; SARS-CoV-2; Torsades de Pointes | 2020 |
Atazanavir: new indication. First-line treatment: fewer gastrointestinal disorders but more cases of jaundice and a risk of torsades de pointes.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Atazanavir Sulfate; Drug Approval; Drug Therapy, Combination; Europe; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Jaundice; Lopinavir; Oligopeptides; Pyridines; Pyrimidinones; Randomized Controlled Trials as Topic; Ritonavir; Torsades de Pointes; Viral Load | 2009 |
Methadone-induced Torsade de pointes after stopping lopinavir-ritonavir.
Topics: Analgesics, Opioid; Anti-Retroviral Agents; Drug Administration Schedule; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; Humans; Lopinavir; Methadone; Middle Aged; Pyrimidinones; Ritonavir; Torsades de Pointes | 2007 |